title: The role of nanomaterials in translational medicine.
abstract: There are a range of definitions for nanomaterials and a range of length scales that are considered nano, but one thing is consistent among fields: nanomaterials are small and special. Nanomaterials have the potential to have tremendous impact on medical treatments. In one example, nanomaterials are permitting the tracking of cells via magnetic resonance imaging (MRI) in clinical trials to assess the efficacy and safety of cellular therapies. In a second example, nanomaterials are acting as drug delivery vehicles for the targeted delivery of therapies to increase efficacy and to reduce side effects. However, there are distinct challenges that must be considered in the development and application of these materials, including careful analysis of the distribution and clearance of nanomaterials and their potential off-target effects. By carefully assessing materials early in their development at the bench, one may be able to move successful approaches through to the clinic more rapidly, which is indeed the goal of the field. For far too many conditions and diseases, the tools we have are less than adequate, and nanomaterials have the potential to fill that void. To realize this potential, investigators must be willing to invest time and resources to develop and to translate these technologies to the point where the risk is low enough that they have real commercial possibilities. Working collaboratively and leveraging resources and experience play important roles in moving technologies through preclinical and clinical testing. It requires incredible dedication of teams of researchers, but the result is new treatments and therapies.
authors: Biomedical Engineering, Case Western Reserve University, Cleveland, Ohio 44106, United States. erin.lavik@case.edu
authors: Erin
authors: E
authors: Lavik
authors: Horst
authors: H
authors: von Recum
references: J Am Coll Cardiol. 2009 Dec 8;54(24):2277-86
references: 19958962
references: Magn Reson Med. 2011 Feb;65(2):564-74
references: 20928883
references: Eur J Cancer. 2008 Apr;44(6):781-90
references: 18331788
references: Trends Biotechnol. 2010 Oct;28(10):517-25
references: 20719399
references: Stem Cells. 2007 Nov;25(11):2739-49
references: 17656645
references: Cytokine Growth Factor Rev. 2009 Oct-Dec;20(5-6):419-27
references: 19926330
references: Sci Transl Med. 2009 Dec 16;1(11):11ra22
references: 20371456
references: Ann Oncol. 2007 Jul;18(7):1159-64
references: 17229768
references: Circulation. 2003 Aug 19;108(7):863-8
references: 12900340
references: Curr Opin Pediatr. 2009 Feb;21(1):30-8
references: 19242239
references: Ann Oncol. 2010 Nov;21(11):2227-2232
references: 20439345
references: Nano Lett. 2007 Jul;7(7):1929-34
references: 17550297
references: Magn Reson Med. 2006 Feb;55(2):242-9
references: 16416426
references: Radiology. 2005 Apr;235(1):155-61
references: 15749976
references: Proc Natl Acad Sci U S A. 2006 Apr 18;103(16):6315-20
references: 16606824
references: Mol Imaging Biol. 2011 Oct;13(5):825-39
references: 20862612
references: Int J Nanomedicine. 2010 Oct 05;5:771-81
references: 21042423
references: Eur J Cancer. 2010 Nov;46(16):3016-21
references: 20801016
references: Discov Med. 2010 Mar;9(46):236-42
references: 20350491
references: J Intern Med. 2010 Jan;267(1):106-18
references: 20059647
references: Nat Rev Cancer. 2008 Jan;8(1):1p following 71; author reply 1p following 71
references: 18159632
references: Arch Neurol. 2010 Oct;67(10):1187-94
references: 20937945
references: Mol Cancer Ther. 2004 Nov;3(11):1451-8
references: 15542784
references: Proc Natl Acad Sci U S A. 2008 Feb 19;105(7):2586-91
references: 18272481
references: Methods Mol Biol. 2010;624:101-17
references: 20217591
references: Anal Bioanal Chem. 2011 Jan;399(1):3-27
references: 20924568
references: Magn Reson Med. 2011 May;65(5):1430-6
references: 21287590
references: Nanomedicine. 2010 Oct;6(5):662-71
references: 20230912
references: Biochimie. 2010 Jun;92(6):601-10
references: 20362028